10:57 AM EDT, 10/31/2025 (MT Newswires) -- AbbVie ( ABBV ) raised its full-year outlook even as weakness in its Humira rheumatoid arthritis medication and cancer drug Imbruvica capped upside potential for third-quarter revenue.

For 2025, the biopharmaceutical company now expects adjusted per-share earnings of $10.61 to $10.65, compared with its prior outlook of $10.38 to $10.58. The guidance includes a $2.05 expense tied to acquired research and development and milestone costs incurred this year through the third quarter. The current consensus on FactSet is for non-GAAP EPS of $10.51.

Revenue is now pegged at about $60.9 billion, $400 million higher than the prior forecast, Chief Financial Officer Scott Reents said on an earnings call, according to a FactSet transcript.

"AbbVie ( ABBV ) continues to deliver outstanding results, with significant momentum across key areas of our portfolio," Chief Executive Robert Michael said in a statement. "We are also making great progress advancing our pipeline and investing in innovation to support AbbVie's ( ABBV ) long-term growth."

For the September quarter, adjusted EPS fell to $1.86 from $3 a year earlier, but exceeded the consensus of $1.77. Revenue grew 9.1% to $15.78 billion, ahead of analysts' $15.59 billion estimate.

Global sales from the immunology portfolio climbed about 12% to $7.89 billion, driven by sharp gains in drugs Skyrizi and Rinvoq. However, Humira's sales tumbled 55% amid biosimilar competition, Chief Commercial Officer Jeffrey Stewart told analysts on the call.

"We continue to anticipate Humira access in the US will decrease throughout the remainder of this year and into 2026, as more plans select exclusionary contracts for existing patients," Stewart said.

In the oncology segment, revenue dropped 0.3% to $1.68 billion as sales of Imbruvica declined about 15%. The aesthetics portfolio fell 3.7% to $1.19 billion, while the neuroscience division logged revenue growth of 20% to $2.84 billion.

Shares of AbbVie ( ABBV ) were down 4.2% in Friday trade.

For the ongoing three-month period, AbbVie ( ABBV ) anticipates adjusted EPS to be in a range of $3.32 to $3.36 and revenue of more than $16.3 billion, Reents said on the call. Analysts are currently projecting non-GAAP EPS of $3.33 and sales of $16.32 billion.

Price: 219.11, Change: -9.09, Percent Change: -3.98